Envoy Medical eliminates $32M debt, gets FDA approval to expand cochlear implant trial

Envoy Medical, Inc.

Extinguished over $32 million in debt, strengthening balance sheet without equity issuance.
Post-quarter: FDA approved expansion of pivotal clinical trial to final stage; three patients enrolled.
Closed up to $16 million registered direct offering priced at-the-market under Nasdaq rules.
Q3 net revenue $42,000; R&D expenses $2.7M; cash $3.556M as of Sept. 30, 2025.
Expanded global patent portfolio with four new patents in U.S., Europe, and Australia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.